{"entity":{"id":"nct06976190","kind":"trial","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","aka":["Magic-C002"],"tldr":"A phase 3 trial of MRG003, Pucotenlimab, Gemcitabine in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.","summary":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT06976190 by Lepu Biopharma Co., Ltd., with 446 participants planned, started 2025-05-06 and due to reach its primary completion in 2029-05. Interventions recorded: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06976190","url":"https://clinicaltrials.gov/study/NCT06976190"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nasopharyngeal","recurrent-metastatic-nasopharyngeal-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["mrg003","pucotenlimab","gemcitabine","docetaxel"],"companies":["lepu-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06976190","phase":"3","setting":"A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","sponsor":"Lepu Biopharma Co., Ltd.","started":"2025-05-06","startedType":"actual","enrolled":446,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06976190/","neighbours":{"cancer":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"mrg003","kind":"drug","name":"MRG003","route":"/drugs/mrg003/"},{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/"}],"company":[{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/"}]}}